Literature DB >> 9652441

Protection against experimental intraabdominal sepsis by two polysaccharide immunomodulators.

A O Tzianabos1, F C Gibson, R L Cisneros, D L Kasper.   

Abstract

Two immunomodulating polysaccharides, poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose (PGG)-glucan and Bacteroides fragilis polysaccharide A (PS A), were evaluated for the prevention of mortality and abscess formation associated with experimental intraabdominal sepsis. Prophylactic treatment with a combination of these compounds significantly reduced mortality (8% vs. 44% in the saline-treated control group) and the incidence of abscesses (30% vs. 100% in the saline-treated control group) after challenge with rat cecal contents. These compounds were also effective when administered therapeutically after bacterial contamination of the peritoneal cavity. PS A treatment conferred long-term protection against abscess formation and resulted in significantly fewer total aerobes and anaerobes in the peritoneal fluid of animals challenged with cecal contents. These data demonstrate the usefulness of two immunomodulatory polysaccharides in preventing experimental intraabdominal sepsis in the absence of antimicrobial therapy and may represent a new adjunct to antibiotic regimens currently used to prevent clinical cases of this disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652441     DOI: 10.1086/515594

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function.

Authors:  A O Tzianabos
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Polysaccharide-experienced effector T cells induce IL-10 in FoxP3+ regulatory T cells to prevent pulmonary inflammation.

Authors:  Jenny L Johnson; Mark B Jones; Brian A Cobb
Journal:  Glycobiology       Date:  2018-12-01       Impact factor: 4.313

3.  Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides.

Authors:  A O Tzianabos; J Y Wang; J C Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

4.  Bacterial capsular polysaccharide prevents the onset of asthma through T-cell activation.

Authors:  Jenny L Johnson; Mark B Jones; Brian A Cobb
Journal:  Glycobiology       Date:  2014-10-27       Impact factor: 4.313

5.  Mgat2 ablation in the myeloid lineage leads to defective glycoantigen T cell responses.

Authors:  Sean O Ryan; Sixto M Leal; Derek W Abbott; Eric Pearlman; Brian A Cobb
Journal:  Glycobiology       Date:  2013-12-04       Impact factor: 4.313

6.  Biological response modifier activity of an exopolysaccharide from Paenibacillus jamilae CP-7.

Authors:  A Ruiz-Bravo; M Jimenez-Valera; E Moreno; V Guerra; A Ramos-Cormenzana
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

7.  Improved antimicrobial host defense in mice following poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose glucan treatment by a gender-dependent immune mechanism.

Authors:  Courtni T Newsome; Estefany Flores; Alfred Ayala; Stephen Gregory; Jonathan S Reichner
Journal:  Clin Vaccine Immunol       Date:  2011-10-05

8.  Polysaccharide A from the capsule of Bacteroides fragilis induces clonal CD4+ T cell expansion.

Authors:  Jenny L Johnson; Mark B Jones; Brian A Cobb
Journal:  J Biol Chem       Date:  2014-12-24       Impact factor: 5.157

9.  Phagocytosis by human neutrophils is stimulated by a unique fungal cell wall component.

Authors:  Ifat Rubin-Bejerano; Claudia Abeijon; Paula Magnelli; Paula Grisafi; Gerald R Fink
Journal:  Cell Host Microbe       Date:  2007-07-12       Impact factor: 21.023

Review 10.  β-Glucan Metabolic and Immunomodulatory Properties and Potential for Clinical Application.

Authors:  Emma J Murphy; Emanuele Rezoagli; Ian Major; Neil J Rowan; John G Laffey
Journal:  J Fungi (Basel)       Date:  2020-12-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.